4-acetoxy-7-methoxycoumarin | 855960-20-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 4-acetoxy-7-methoxycoumarin
• 英文别名: 4-O-acetyl-7-methoxycoumarin；4-Acetoxy-7-methoxy-cumarin；(7-Methoxy-2-oxochromen-4-yl) acetate
• CAS: 855960-20-2
• 化学式: C₁₂H₁₀O₅
• 分子量: 234.208
• InChiKey: DNWQMMXRZUXSSW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-acetoxy-7-methoxycoumarin 在 potassium cyanide 、 18-冠醚-6 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 72.0h， 以88%的产率得到3-acetyl-4-hydroxy-7-methoxycoumarin
  参考文献：
  名称：

  Design and Synthesis of a Coumarin-based Acidichromic Colorant

  摘要：

  本文介绍了通过在香豆素分子上加入供电子和吸电子取代基对含香豆素的着色剂 1 的酸性变色特性进行微调的方法。在强酸性和碱性条件下，着色剂 1 可以发生两种截然不同且可逆的颜色变化，但在气态氨存在下则不能。结果表明，溴代化合物 5b 在溶液中和聚碳酸酯薄膜上遇到气态氨时都会由红色变为黄色，这表明香豆素分子 7 位上的抽电子基团使 5b 上的烯醇氢比未取代的化合物 1 更容易受到碱的去质子化作用。

  DOI：

  10.3390/12071316
• 作为产物：
  描述：

  4-羟基-7-甲氧基香豆酯 、 乙酸酐 反应 2.0h， 生成 4-acetoxy-7-methoxycoumarin
  参考文献：
  名称：

  新型4-羟基-7-羟基-和3-羧基香豆素衍生物的合成及抗菌活性

  摘要：

  香豆素衍生物用作荧光染料和药物。它们还具有一些显着的生理作用，包括某些黄曲霉毒素的急性肝毒性和致癌性、双香豆素的抗凝作用以及新生霉素和香豆素 A1 的抗菌活性。由于目前耐药菌株的数量不断增加，新的抗菌化合物的合成是治疗传染病的关键方法之一。因此，合成了一系列香豆素取代的衍生物，即4-羟基和7-羟基香豆素，以及3-羧基香豆素。4-羟基香豆素衍生物 4a-c 经历了重排反应。4- 和 7- 羟基香豆素都用活化的氮丙啶处理，产生了一系列开环产物 7、8、10 和 11。通过脂肪族烷基胺和烷基二胺与 PyBOP 和 DIEA 反应制备 3-羧基香豆素酰胺二聚体衍生物 14-21。在这项研究中，我们使用了一种称为改良微孔板抗生素药敏试验方法 (MMAST) 的新技术，该技术比以前的方法更方便、更高效、更准确，并且只需要少量样品即可进行检测。一些化合物是通过与酸酐反应产生的，并显示出抑制革兰氏阳性微生

  DOI：

  10.3390/molecules170910846

文献信息

• [EN] 3,4-DIHYDRO-PYRROLO[1,2-a]PYRAZIN-1-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)<br/>[FR] DÉRIVÉS DE 3,4-DIHYDRO-PYRAZOLO[1,2-A]PYRAZIN-1-YLAMINE UTILES EN TANT QU'INHIBITEURS DE BÊTA-SÉCRÉTASE (BACE)
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2012120023A1

  公开（公告）日：2012-09-13

  The present invention relates to novel 3,4-dihydro-pyrrolo[l,2-a]pyrazin-1-ylamine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid.

  本发明涉及作为β-分泌酶抑制剂的新型3,4-二氢吡咯并[l,2-a]吡嗪-1-胺衍生物，该酶也被称为β-位点淀粉样蛋白裂解酶、BACE、BACE1、Asp2或memapsin2。该发明还涉及包含这些化合物的药物组合物，用于制备这些化合物和组合物的方法，以及将这些化合物和组合物用于预防和治疗涉及β-分泌酶的疾病，如阿尔茨海默病（AD）、轻度认知障碍、老年痴呆、带有Lewy小体的痴呆、唐氏综合征、与中风相关的痴呆、与帕金森病相关的痴呆或与β-淀粉样蛋白相关的痴呆。
• [EN] INHIBITORS OF BETA SECRETASE<br/>[FR] INHIBITEURS DE BÊTA-SÉCRÉTASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018162443A1

  公开（公告）日：2018-09-13

  The present invention relates to tricyclic inhibitors of beta-secretase having the structure shown in Formula (I) and (II) and the tautomers and the stereoisomeric forms thereof, wherein the radicals are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease, dementia associated with beta-amyloid, age-related macular degeneration, type 2 diabetes and other metabolic disorders.

  本发明涉及具有式(I)和(II)所示结构的β-分泌酶的三环抑制剂及其互变异构体和立体异构体，其中自由基如说明书中所定义。本发明还涉及包含这些化合物的药物组合物，制备这些化合物和组合物的方法，以及使用这些化合物和组合物预防和治疗β-分泌酶参与的疾病，如阿尔茨海默病(AD)、轻度认知障碍、老年性痴呆、痴呆、路易体痴呆、唐氏综合症、与中风相关的痴呆、与帕金森病相关的痴呆、与β-淀粉样蛋白相关的痴呆、年龄相关性黄斑变性、2型糖尿病和其他代谢紊乱。
• 4,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-6-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
  申请人：Trabanco-Suárez Andrés Avelino

  公开号：US20130190318A1

  公开（公告）日：2013-07-25

  The present invention relates to novel 4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-yl-amine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid.

  本发明涉及作为β-分泌酶抑制剂的新型4,7-二氢吡唑并[1,5-a]吡嗪-6-基胺衍生物，该酶也被称为β-位点淀粉样蛋白裂解酶、BACE、BACE1、Asp2或memapsin2。该发明还涉及包含这些化合物的药物组合物，制备这些化合物和组合物的方法，以及利用这些化合物和组合物预防和治疗涉及β-分泌酶的疾病，如阿尔茨海默病（AD）、轻度认知障碍、老年痴呆、带有Lewy小体的痴呆、唐氏综合征、与中风相关的痴呆、与帕金森病相关的痴呆或与β-淀粉样蛋白相关的痴呆。
• [EN] 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 2,3,4,5-TÉTRAHYDROPYRIDINE-6-AMINE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2017050978A1

  公开（公告）日：2017-03-30

  The present invention relates to 2,3,4,5-tetrahydropyridin-6-amine compound inhibitors of beta-secretase having the structure shown in Formula (I) wherein the radicals are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease, or dementia associated with beta-amyloid.

  本发明涉及具有如公式(I)所示结构的β-分泌酶抑制剂2,3,4,5-四氢吡啶-6-胺化合物，其中基团如规范中所定义。该发明还涉及包括这些化合物的药物组合物，用于制备这些化合物和组合物的方法，以及利用这些化合物和组合物预防和治疗涉及β-分泌酶的疾病，如阿尔茨海默病（AD）、轻度认知障碍、老年痴呆、带有Lewy小体的痴呆、唐氏综合征、与中风相关的痴呆、与帕金森病相关的痴呆或与β-淀粉样蛋白相关的痴呆。
• [EN] SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS<br/>[FR] HYDANTOÏNAMIDES SUBSTITUÉS UTILISÉS EN TANT QU'ANTAGONISTES D'ADAMTS7
  申请人：BAYER AG

  公开号：WO2021094436A1

  公开（公告）日：2021-05-20

  The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; R2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R3, R4, R5, R6, R7 and R8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R2, R3, R4 is H; X1, X2, X3, X4, X5 and X6 are independently N or C; with the proviso that in each ring maximal one X is N.

  本申请涉及式(I)所示的取代脒酰胺作为ADAMTS7拮抗剂，涉及它们的制备过程，以及它们单独或组合用于治疗或预防疾病，特别是心血管疾病，包括动脉粥样硬化、冠心病(CAD)、外周血管病(PAD)、动脉闭塞性疾病或血管成形术后的再狭窄。R1是氢、烷基、环烷基、杂环烷基、杂芳基或苯基；R2是氢、氰基、卤素、烷基亚磺酰基、烷基、环烷基或烷氧基；R3、R4、R5、R6、R7和R8独立的是氢、卤素、烷基或烷氧基；大多数基团可被选择性地取代；条件是至少R2、R3、R4中的一个为H；X1、X2、X3、X4、X5和X6独立的是N或C；条件是每个环中最多只有一个X是N。